What's Happening?
The OPTIMA trial, presented at ASCO 2026, has revealed that a tumor gene expression test could allow millions of women with breast cancer to avoid unnecessary chemotherapy. Conducted by researchers at University College London and the University of Glasgow,
the trial involved over 4,400 women aged 40 or above with newly diagnosed breast cancer across several countries. The genomic testing used Veracyte's Prosigna assay to measure the activity of 50 genes in tumor tissue. Results showed that women with HR-positive, HER2-negative breast cancer, who were identified by the test as unlikely to benefit from chemotherapy, had similar outcomes with hormonal therapy alone. The study found that invasive breast cancer free survival was 91.5% in the control group and 90.4% in those who received only hormonal therapy, meeting the threshold for non-inferiority.
Why It's Important?
This development is significant as it could transform breast cancer treatment by sparing many patients from the physical and emotional burdens of chemotherapy, which often comes with severe side effects. For healthcare systems, this approach represents a more efficient use of resources, potentially saving costs associated with chemotherapy. The trial's findings could lead to more personalized treatment plans, improving the quality of life for patients and optimizing healthcare delivery. The researchers estimate that this could help 5,000 NHS breast cancer patients avoid chemotherapy annually, highlighting the potential for widespread impact.
What's Next?
The next phase of the OPTIMA trial will investigate the use of the Prosigna test in a younger demographic, specifically premenopausal women with this form of breast cancer, to determine if they too can safely avoid chemotherapy. However, data from this phase will not be available for several years. The ongoing research aims to further refine and expand the applicability of genomic testing in breast cancer treatment, potentially influencing future clinical guidelines and standard care practices.
